Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease.
about
Generation of high-affinity DNA aptamers using an expanded genetic alphabetAptamers in TherapeuticsSelection and Biosensor Application of Aptamers for Small MoleculesAdvanced drug delivery and targeting technologies for the ocular diseasesModified Nucleoside Triphosphates for In-vitro Selection TechniquesOcular Complications of Diabetes and Therapeutic ApproachesMethods for Improving Aptamer Binding AffinityFrom selection hits to clinical leads: progress in aptamer discoveryAptamers: A promising chemical antibody for cancer therapyBioengineering of noncoding RNAs for research agents and therapeuticsCorneal neovascularization and biological therapyGeneration of Aptamers with an Expanded Chemical RepertoireNucleic acid aptamers: research tools in disease diagnostics and therapeuticsBiosafe nanoscale pharmaceutical adjuvant materialsWaveguide-mode sensors as aptasensorsReceptor tyrosine kinase-mediated angiogenesisOligonucleotide Therapies: The Past and the PresentAptamers in diagnostics and treatment of viral infectionsmiRNA-based therapies: strategies and delivery platforms for oligonucleotide and non-oligonucleotide agentsSmart functional nucleic acid chimeras: enabling tissue specific RNA targeting therapyCS-SELEX Generates High-Affinity ssDNA Aptamers as Molecular Probes for Hepatitis C Virus Envelope Glycoprotein E2A Structural Explanation for the Antithrombotic Activity of ARC1172, a DNA Aptamer that Binds von Willebrand Factor Domain A1Conformational plasticity of RNA for target recognition as revealed by the 2.15 A crystal structure of a human IgG-aptamer complexAn Exocyclic Methylene Group Acts As a Bioisostere of the 2′-Oxygen Atom in LNASynthesis, Improved Antisense Activity and Structural Rationale for the Divergent RNA Affinities of 3′-Fluoro Hexitol Nucleic Acid (FHNA and Ara-FHNA) Modified OligonucleotidesSynthesis and Antisense Properties of Fluoro Cyclohexenyl Nucleic Acid (F-CeNA), a Nuclease Stable Mimic of 2′-Fluoro RNAStructural basis for specific inhibition of Autotaxin by a DNA aptamerTherapeutic aptamers: developmental potential as anticancer drugsEfficient reverse transcription using locked nucleic acid nucleotides towards the evolution of nuclease resistant RNA aptamersDiscovering aptamers by cell-SELEX against human soluble growth factors ectopically expressed on yeast cell surfacesFlt Multivalent Conjugates Inhibit Angiogenesis and Improve Half-Life In VivoXNA marks the spot. What can we learn about the origins of life and the treatment of disease through artificial nucleic acids?RNA plasticity and selectivity applicable to therapeutics and novel biosensor developmentA neutralizing RNA aptamer against EGFR causes selective apoptotic cell deathFit for the Eye: Aptamers in Ocular DisordersBlind tests of RNA nearest-neighbor energy predictionAcousto-microfluidics for screening of ssDNA aptamer.Nucleic Acid Aptamers as Potential Therapeutic and Diagnostic Agents for Lymphoma.Adhesion through single peptide aptamers.Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy
P2860
Q22122129-73438725-881A-4A57-BC4B-024871FABE55Q26738413-64A9A4BB-D339-404A-B50B-3915DEEB562CQ26744467-D2493411-F5E1-4911-9C82-15B519712C8EQ26747220-7836CC9E-1437-402E-932D-942014B62533Q26747256-C1AC0432-19F1-4806-AF1D-55FCBF48CFBAQ26749412-C8FFE06E-A6DD-4E6B-974C-66AB618077DCQ26752642-F9775F35-67E0-41AF-AD26-1D04C10F6FCBQ26752799-ED4DF98C-C575-4374-AABF-B7B86CE0AA4FQ26766832-97F7789C-A9B6-447A-BEA9-9909DEA72D17Q26772092-184636C4-B169-4AE6-91F4-1B00DCC58120Q26776229-7E8FA42F-EC02-4FE1-951F-2EC4E7C6272EQ26782794-EBA90E6B-71BA-478C-B59C-1BCC4B8B5004Q26824321-B8EA1CD4-551E-44F2-A918-BEBFAB7F8ABDQ26829798-5114E2F4-F30F-4F0E-98B3-46654153A306Q26996166-B36DECD2-F4E5-49B9-806C-C5251919AB41Q27001612-83DA9D78-E3B2-4502-BD81-9F9FB1979D96Q27002403-33CC8CC5-387F-4D03-BAD6-6E299F438330Q27014527-E835868F-255B-406C-8175-55688318795FQ27023295-CF0A0DE2-7388-410A-8826-D248F1E4FA81Q27025832-4FAD083C-F797-4ECC-B655-057EFAB13154Q27490421-0D6590CA-4960-489E-84A9-BF402654B44AQ27658166-CAEA4080-B073-4F95-AE2E-1AB6B3CC0D45Q27663735-38675EA9-AD48-4038-993A-DCA88F50CACBQ27664845-0544CEAF-58E4-43E7-B186-41AABAF127D5Q27673978-6E22469A-794D-48AA-BFB1-EFCEB189C024Q27679106-6AF4A36A-CD83-47D3-9768-A7B07B99D973Q27704519-0182883A-9664-411B-B433-2A095EA7A2A0Q28085157-71322566-2A6C-4CA7-8B6B-94DB1BF0F4E8Q28482539-E5667CB6-45EE-4631-BAF9-6B0053489F46Q28541656-5ACA014E-42AF-497D-B357-07A4909EC214Q28552652-B153809F-31AC-4D5E-B0E8-3CF5A14418D0Q28706271-B23BB406-0F2D-41CD-BC84-56290D9C57CCQ28727743-D9E6E5F8-519E-48FB-98E8-9944B00332FCQ28740749-103B1A40-4CC9-4C62-9225-926E5FCE2E4BQ28828283-45FC1CED-3933-45F3-884D-BA28135A4C6EQ28828288-75F05706-D40E-4246-A44A-BB63B6111F36Q30381725-C9F61097-DED3-462F-9604-D070B69A0A03Q30434521-092C7739-2228-411B-AC93-F58BD913C8A2Q30437104-F4D1F02C-E122-49B4-8352-87DD6C41290CQ30455612-E658C122-A182-44B1-8144-775454B423CD
P2860
Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease.
description
2006 nî lūn-bûn
@nan
2006 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease.
@ast
Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease.
@en
Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease.
@nl
type
label
Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease.
@ast
Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease.
@en
Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease.
@nl
prefLabel
Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease.
@ast
Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease.
@en
Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease.
@nl
P2093
P2860
P356
P1476
Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease.
@en
P2093
Anthony P Adamis
David R Guyer
David T Shima
Emmett T Cunningham
Eugene W M Ng
Perry Calias
P2860
P2888
P304
P356
10.1038/NRD1955
P577
2006-02-01T00:00:00Z